Biobizkaia
Forschungszentrum
Centre Hospitalier de l’Université de Montréal
Montreal, CanadáPublikationen in Zusammenarbeit mit Forschern von Centre Hospitalier de l’Université de Montréal (18)
2023
-
A second update on mapping the human genetic architecture of COVID-19
Nature
-
Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis
JAMA Neurology, Vol. 80, Núm. 7, pp. 702-713
-
Disability accrual in primary and secondary progressive multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 9, pp. 707-717
-
Effectiveness of multiple disease-modifying therapies in relapsing-remitting multiple sclerosis: causal inference to emulate a multiarm randomised trial
Journal of neurology, neurosurgery, and psychiatry, Vol. 94, Núm. 12, pp. 1004-1011
-
Erratum to: Mapping the human genetic architecture of COVID-19 (Nature, (2021), 600, 7889, (472-477), 10.1038/s41586-021-03767-x)
Nature
-
The risk of secondary progressive multiple sclerosis is geographically determined but modifiable
Brain : a journal of neurology, Vol. 146, Núm. 11, pp. 4633-4644
2022
-
Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis
Neurology, Vol. 99, Núm. 17, pp. E1926-E1944
-
Heterogeneity on long-term disability trajectories in patients with secondary progressive MS: a latent class analysis from Big MS Data network
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 94, Núm. 1, pp. 23-30
-
lncRNA deregulation in childhood acute lymphoblastic leukemia: A systematic review
International journal of oncology, Vol. 60, Núm. 5
2021
-
Disability outcomes of early cerebellar and brainstem symptoms in multiple sclerosis
Multiple Sclerosis Journal, Vol. 27, Núm. 5, pp. 755-766
-
Impact of Bacillus Calmette-Gue´rin (BCG) vaccination on postoperative mortality in patients with perioperative SARS-CoV-2 infection
BJS Open
-
Machine learning risk prediction of mortality for patients undergoing surgery with perioperative SARS-CoV-2: The COVIDSurg mortality score
British Journal of Surgery, Vol. 19, Núm. 4
2020
-
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
Brain, Vol. 143, Núm. 9, pp. 2742-2756
-
Risk of secondary progressive multiple sclerosis: A longitudinal study
Multiple Sclerosis Journal, Vol. 26, Núm. 1, pp. 79-90
2019
-
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis
Journal of Neurology, Neurosurgery and Psychiatry, Vol. 90, Núm. 4, pp. 458-468
2018
-
Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis
Multiple Sclerosis Journal, Vol. 24, Núm. 12, pp. 1569-1577
2017
-
Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study
The Lancet Neurology, Vol. 16, Núm. 4, pp. 271-281
2013
-
Breast cancer in systemic lupus erythematosus
Oncology (Switzerland), Vol. 85, Núm. 2, pp. 117-121